A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases


The transfusion of regulatory T cells (Tregs) has been used in the clinic to successfully prevent graft vs. host disease and is currently being evaluated in the treatment of other autoimmune diseases, such as organ graft rejection, type 1 diabetes and multiple sclerosis. Prior to transfusion, adoptive regulatory T cell transfer requires the expansion of regulatory T cells in culture; this results in a mixed population of regulatory T cells that limits the effectiveness of the transferred cells.

Scientists at the NIH have developed a method that promotes the expansion of regulatory T cells that are longer lived, more stable, and more suppressive of the autoimmune response. By supplementing T cell cultures with DNA oligonucleotides, the inventors were able to enrich the regulatory T cell population that enhanced the suppression of the autoimmune response. This method has the potential to more effectively generate regulatory T cells for the treatment of autoimmune diseases.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of autoimmune diseases, such as Graft vs. Host Disease, Organ Graft Rejection Type 1 Diabetes, Multiple Sclerosis.
 
  • More effective therapy when compared to traditional T cell expansion methods.
  • Expansion method is inexpensive and similar to current methods.


Development Stage:
In vitro data available

Inventors:

Yong Chan Kim (NIAID)  ➽ more inventions...

Ethan Shevach (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 15/284,840
US Application No. 61/576,837
US Application No. 13/716,900

Publications:
Kim Y, et al. PMID 22294730

Licensing Contact:
Benjamin Hurley, Ph.D.
Email: benjamin.hurley@nih.gov
Phone: 240-669-5092

OTT Reference No: E-279-2011/0
Updated: Sep 9, 2015